Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.57 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13949629 | 0.87 | MEN1 (0.54) | NAMPTHDAC1MEN1KMT2AF10 | |
| SCHEMBL17472423 | 0.87 | HDAC1 (0.65) | CACNA1BAPBA1NAMPTHDAC1F10 | |
| SCHEMBL2981566 | 0.87 | CACNA1B (0.49) | CACNA1BAPBA1NAMPTHDAC1MEN1 | |
| SCHEMBL2829176 | 0.86 | POLB (0.56) | NAMPTHDAC1MEN1KMT2AF10 | |
| SCHEMBL30091852 | 0.85 | HDAC1 (0.61) | CACNA1BAPBA1NAMPTHDAC1F10 | |
| SCHEMBL2138082 | 0.85 | HDAC1 (0.61) | CACNA1BAPBA1NAMPTHDAC1MEN1 | |
| SCHEMBL15551962 | 0.85 | HDAC1 (0.61) | CACNA1BAPBA1NAMPTHDAC1F10 | |
| SCHEMBL24890579 | 0.85 | NAMPT (0.57) | CACNA1BAPBA1NAMPTHDAC1MEN1 | |
| SCHEMBL3662421 | 0.85 | F10 (0.53) | NAMPTHDAC1MEN1KMT2AF10 | |
| SCHEMBL12772560 | 0.85 | NPC1 (0.57) | NAMPTHDAC1MEN1KMT2AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4093730-B1 | HDAC DEGRADER | UNIV LEICESTER (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20230120211-A1 | HDAC Degrader | UNIVERSITY OF LEICESTER (GB) | 2023-04-20 | — | — | US | disclosed |
| EP-4093730-A1 | HDAC DEGRADER | University of Leicester (GB) | 2022-11-30 | — | — | EP | disclosed |
| US-9266822-B2 | Solid forms of tacedinaline | THE BROAD INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266822-B2 | Solid forms of tacedinaline | THE BROAD INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-8841346-B2 | Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841346-B2 | Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140275268-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275268-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8729130-B2 | Methods of using novel solid forms of tacedinaline | THE BROAD INSTITUTE, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8563615-B2 | Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563615-B2 | Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130150450-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150450-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130102677-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102677-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120322879-A1 | USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-12-20 | — | — | US | disclosed |
| WO-2012003413-A1 | NOVEL SOLID FORMS OF TACEDINALINE | THE BROAD INSTITUTE, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20110224303-A1 | USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS | MASSACHUSETTS GENERAL HOSPITAL | 2011-09-15 | — | — | US | disclosed |
| WO-2011053876-A1 | THE USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322879-A1 | USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS | CHRNA4, SLC6A4, CHRNB4 | CACNA1B 260/4885APBA1 1428/4885NAMPT 627/4885 |
| US-20110224303-A1 | USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS | CHRNA4, SLC6A4, CHRNB4 | CACNA1B 260/4885APBA1 1428/4885NAMPT 627/4885 |
| US-20130102677-A1 | NOVEL SOLID FORMS OF TACEDINALINE | ACSS2, SLC10A1, ACAT2 | CACNA1B 2629/4885APBA1 285/4885NAMPT 1469/4885 |
| US-20230120211-A1 | HDAC Degrader | HDAC1, HDAC11, HDAC3 | CACNA1B 4547/4885APBA1 2986/4885NAMPT 1329/4885 |
| US-20130150450-A1 | NOVEL SOLID FORMS OF TACEDINALINE | ACSS2, SLC10A1, ACAT2 | CACNA1B 2629/4885APBA1 285/4885NAMPT 1469/4885 |
| US-20140275268-A1 | NOVEL SOLID FORMS OF TACEDINALINE | ACSS2, FAM162A, ACAT2 | CACNA1B 2338/4885APBA1 170/4885NAMPT 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.